Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nurulimab - Biocad

Next Previous
Search
Drug Profile

Nurulimab - Biocad

Alternative Names: Anti-CTLA4 MAB - Biocad; BCD-145

Latest Information Update: 03 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 31 May 2024 Efficacy, pharmacodynamics and adverse events data from a phase I trial in melanoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in Russia (IV, Infusion)
  • 04 Dec 2018 Biocad completes a phase I trial in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in Russia (IV) (NCT03472027)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top